State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China; Department of Ophthalmology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Clin Immunol. 2023 Jun;251:109633. doi: 10.1016/j.clim.2023.109633. Epub 2023 May 5.
To investigate the efficacy and safety of dexamethasone (DEX) implant, Ozurdex ®, as an adjunctive treatment for refractory Behçet's uveitis (BU), a total of 61 patients (80 eyes) were included in this cross-sectional study and divided into the non-DEX and DEX groups. After >12 months of treatment, the improvement in the fluorescein angiography score and vitritis score was significantly higher in the DEX group than in the non-DEX group. Although the posterior capsule opacification score was exacerbated, the rate of low-dose systemic glucocorticoid was higher and the relapse times were fewer in the DEX group. Therefore, Ozurdex® is an effective and safe option for patients with BU that are refractory to systemic immunosuppressant treatments by controlling vasculitis, stabilizing vitreous inflammation, preventing recurrence, and reducing daily glucocorticoid doses.
为了研究地塞米松（DEX）植入物（Ozurdex®）作为难治性贝赫切特葡萄膜炎（BU）辅助治疗的疗效和安全性，共有 61 名患者（80 只眼）纳入本横断面研究，并分为非 DEX 组和 DEX 组。经过>12 个月的治疗，DEX 组在荧光素血管造影评分和前葡萄膜炎评分方面的改善明显高于非 DEX 组。尽管后囊混浊评分恶化，但 DEX 组的低剂量全身糖皮质激素使用率更高，复发次数更少。因此，Ozurdex®是一种有效且安全的选择，可通过控制血管炎、稳定玻璃体炎症、预防复发和减少每日糖皮质激素剂量，用于治疗对全身免疫抑制剂治疗反应不佳的 BU 患者。
